HomeCompareVIAP vs VYM

VIAP vs VYM: Dividend Comparison 2026

VIAP yields 400000.00% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIAP wins by $5.011119029548644e+32M in total portfolio value
10 years
VIAP
VIAP
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full VIAP calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — VIAP vs VYM

📍 VIAP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIAPVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIAP + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIAP pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIAP
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, VIAP beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIAP + VYM for your $10,000?

VIAP: 50%VYM: 50%
100% VYM50/50100% VIAP
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIAP buys
0
VYM buys
0
No recent congressional trades found for VIAP or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIAPVYM
Forward yield400000.00%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$5.011119029548644e+32M$27.8K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$278.55
Total dividends collected$5.010957816668433e+32M$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VIAP vs VYM ($10,000, DRIP)

YearVIAP PortfolioVIAP Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$40,010,700$40,000,000.00$11,151$241.44+$40.00MVIAP
2$149,615,521,729$149,572,710,280.37$12,413$246.79+$149615.51MVIAP
3$522,880,052,725,200$522,719,964,116,949.25$13,794$251.79+$522880052.71MVIAP
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$15,306$256.47+$1707862989289.03MVIAP
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$16,960$260.84+$5213509402845684.00MVIAP
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$18,768$264.92+$14874219058409543680.00MVIAP
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$20,745$268.71+$3.966119623405075e+22MVIAP
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$22,905$272.24+$9.88384363503273e+25MVIAP
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$25,265$275.51+$2.302052364743449e+29MVIAP
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$27,842$278.55+$5.011119029548644e+32MVIAP

VIAP vs VYM: Complete Analysis 2026

VIAPStock

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.

Full VIAP Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this VIAP vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIAP vs SCHDVIAP vs JEPIVIAP vs OVIAP vs KOVIAP vs MAINVIAP vs VIGVIAP vs DGROVIAP vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.